{"classes":[{"categories":[{"measurements":[{"comment":"Geometric CV was not calculated as data were available for only two participants.","groupId":"OG000","spread":"NA","value":"17.0"},{"groupId":"OG001","spread":"94.8","value":"20.3"},{"groupId":"OG002","spread":"39.9","value":"61.8"},{"groupId":"OG003","spread":"61.8","value":"79.0"},{"groupId":"OG004","spread":"46.8","value":"108"},{"groupId":"OG005","spread":"38.0","value":"160"},{"groupId":"OG006","spread":"54.0","value":"168"},{"groupId":"OG007","spread":"29.2","value":"163"},{"groupId":"OG008","spread":"26.3","value":"297"},{"groupId":"OG009","spread":"19.1","value":"208"},{"groupId":"OG010","spread":"4.2","value":"337"},{"groupId":"OG011","spread":"26.2","value":"353"},{"comment":"Geometric mean and CV were not calculated as data were available for only one participant.","groupId":"OG012","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"3"},{"groupId":"OG011","value":"4"},{"groupId":"OG012","value":"1"}],"units":"Participants"}],"description":"Cavg0-24h was defined as average concentration from time 0 to 24 hours.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received selinexor dose of 3 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG000","title":"Selinexor (3 mg/m^2)"},{"description":"Participants received selinexor dose of 6 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG001","title":"Selinexor (6 mg/m^2)"},{"description":"Participants received selinexor dose of 12 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 10, 15, 17, 19, 22 and 24 in schedule 1.","id":"OG002","title":"Selinexor (12 mg/m^2)"},{"description":"Participants received selinexor dose of 16.8 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 5, 8, 15, 17, 19, and 22 in schedule 2.","id":"OG003","title":"Selinexor (16.8 mg/m^2)"},{"description":"Participants received selinexor dose of 23 mg/m\\^2 orally at Cycle 1, on Day 1 and 2 of each week for a 28-day cycle in schedule 4.","id":"OG004","title":"Selinexor (23 mg/m^2)"},{"description":"Participants received selinexor dose of 30 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 4, 8, 10, 15 and 17 in schedule 3, 5 and 9.","id":"OG005","title":"Selinexor (30 mg/m^2)"},{"description":"Participants received selinexor dose of 35 mg/m\\^2 orally at Cycle 1, on Day 1 and 3 in schedule 6.","id":"OG006","title":"Selinexor (35 mg/m^2)"},{"description":"Participants received selinexor dose of 40 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, 17 followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 8 and 11.","id":"OG007","title":"Selinexor (40 mg/m^2)"},{"description":"Participants received selinexor dose of 46 mg/m\\^2 orally at Cycle 1, on Day 1 once-weekly in schedule 7.","id":"OG008","title":"Selinexor (46 mg/m^2)"},{"description":"Participants received selinexor dose of 55 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, and 10, followed by an 18-day treatment-free interval (Days 11 through 28) in schedule 10.","id":"OG009","title":"Selinexor (55 mg/m^2)"},{"description":"Participants received selinexor dose of 60 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG010","title":"Selinexor (60 mg/m^2)"},{"description":"Participants received selinexor dose of 70 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG011","title":"Selinexor (70 mg/m^2)"},{"description":"Participants received selinexor dose of 80 mg/m\\^2 orally at Cycle 1, on Day 1, 3, 8, 10, 15, and 17, followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG012","title":"Selinexor (80 mg/m^2)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis was defined as all participants who received active drug, selinexor, without the co-administration of another chemotherapeutic (i.e., rituximab), and for whom the PK profile for C1D1 could be adequately characterized. Here 'Overall Number of Participants Analyzed' signifies number of participants analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"0 (pre-dose), 0.5, 1, 2, 4, 8, 24 and 48 hours post-dose on Day 1, 8 of Cycle 1 and Days 15, 16 or 17 of Cycle 2","title":"Average Concentration From Time 0 to 24 Hours (Cavg0-24h) of Selinexor","type":"SECONDARY","unitOfMeasure":"ng/mL"}